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Analysis of Chimeric Polypeptides
The purity of the CPs was visually determined by SDS-PAGE, using 4-20% Tris-HCl Ready Gels (Bio-Rad, Hercules, CA) stained with CuCl 2 (0.5 M) ( Figure S3 ).
Conjugation of Molecules to Chimeric Polypeptides
15 mg of lyophilized CP was resuspended in 800 µL of 100 mM phosphate buffer, pH 7.4, and spiked with an additional 100 µL of 100 mM TCEP in water, pH 7.4. To generate the CP nanoparticles used to build the model, 100 µL of a 50 mM solution of n-benyzl maleimide in DMSO was added to the CP solution drop-wise, and allowed to mix for 3 h at room temperature. To create fluorescent CP micelles, 0.2 mg of Rhodamine Red-X succinimidyl ester (Life Technologies; Carlsbad, CA) dissolved in 100 µL of DMSO was added to the CP solution dropwise, and allowed to mix for 3 h at room temperature. 3 mg of n-pyrenyl maleimide in 100 µL of DMSO was then added to the CP-Rhodamine solution dropwise, and allowed to mix for an additional 16 h at room temperature. Following conjugation, the CP conjugate was centrifuged at 13,000 g and 4°C for 10 min and purified by passage through a size exclusion column (PD10, GE Healthcare) and dialysis in ddH 2 O overnight. The solution was then lyophilized and stored at -20°C for future use.
Thermal Turbidimetry
The optical density at 350 nm (OD 350 ) of each CP was measured as a function of temperature on a UV-vis spectrophotometer equipped with a multicell thermoelectric temperature controller (Cary 300, Varian Instruments; Walnut Creek, CA). CP solutions in PBS ranging in concentration from 2 to 100 µM were heated at a rate of 1°C/min. The T t was defined as the inflection point of the turbidity plot. To measure the transition in 90% fetal bovine serum (FBS), a 500 µM CP solution was diluted 10-fold into the FBS solution.
Conjugation of Doxorubicin
The conjugation of Dox to the CPs was performed as described elsewhere 3 with slight modifications. Dox was conjugated to the unique cysteine residues located on the C-terminus of the CP using the heterobifunctional linker n-β-maleimidopropionic acid hydrazide (BMPH; Pierce Biotechnology, Rockford, IL) in a two-step process ( Figure S5 ). First, Dox (215 mg) and BMPH (100 mg) were co-dissolved in 100 mL of anhydrous methanol spiked with 100 µL of trifluoroacetic acid. This solution was stirred for 16 h at 20°C in the dark, dried using rotary evaporation, and then resuspended in 20 mL methanol. In the second step, this solution was immediately added dropwise to a solution containing the CP. Prior to this reaction, the CP was purified as described previously, incubated with a high capacity endotoxin removal resin (Thermo Scientific) for 2 h, and passed through a 0.2 µm filter. The CP solution was then incubated in 50 mM TCEP for 1 h at 20°C to eliminate disulfide crosslinking. Phase separation was triggered by the addition of crystallized NaCl to a final concentration of 1-3 M to remove excess TCEP and concentrate the CP solution. The pellet was then resuspended to a final concentration of 8.6 µmoles of CP in 10 mL of phosphate buffer (100 mM phosphate, 1 mM EDTA, pH 7.4). This solution was stirred for 3 h at 20°C in the dark, spiked with 1 mL of 100 mM TCEP (dissolved in water, pH 7.4), and then stirred for an additional 16 h. To purify the CP-Dox product, the methanol was first evaporated under a constant stream of N 2 to a total of 10 mL. A solution of 5 M NaCl was added to the CP-Dox solution to trigger phase separation (a 1:1 S4 ratio was usually sufficient). This solution was centrifuged (5000 g, 10 min, 25°C), and the supernatant was discarded. The CP-Dox pellet was resuspended in PBS and centrifuged once more to remove any insoluble reactants (14000 g, 10 min, 25°C). Finally, the CP was purified from any remaining free drug reactants by passing the solution through a size exclusion column (PD10, GE Healthcare), dialyzing for 24-48 h (MWCO = 10-12 kDa) in 5 mM ammonium carbonate (pH 8.0), lyophilized, and stored at -20ºC for later use. The degree of Dox conjugation to the CP was measured for each sample by resuspending 10-20 mg of lyophilized CP-Dox in 1 mL of PBS, and then dividing the concentration of Dox, determined by UV-vis spectroscopy, by the concentration of CP. The CP concentration was determined gravimetrically from the lyophilized sample by adjusting for the added mass from the attached Dox-linker.
In Vitro Cytotoxicity C26 murine colon carcinoma cells were maintained in complete media consisting of RPMI-1640 supplemented with 10% FBS, 4.5 g/L D-glucose, 10 mM HEPES, and 1 mM sodium pyruvate. Cells were maintained at 37°C and 5% CO 2 and passaged every 3 days. In vitro cytotoxicity was determined through the use of a colorimetric assay. 5x10 3 C26 cells were seeded per 100 µL media on BD Falcon TM 96-well cell culture plates (BD; Franklin Lakes, NJ) and allowed to adhere for 24 h. The cell media was then removed and replaced with 120 µL complete media containing Dox or CP-Dox nanoparticles. The cells were incubated for 72 h at 37°C, after which 20 µL of CellTiter 96 AQueous TM (Promega; Madison, WI) 3-(4,5,-dimethyl2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent was added to each well. The cells were incubated for an additional 30 min, and the absorbance of the solution was measured at 490 nm on a Victor 3 microplate reader (Perkin Elmer; Waltham, MA). To calculate the IC 50 , the data were fit to the equation: Viability = 1 / (1 + (C Dox /IC 50 ) p ), where C Dox is the effective Dox concentration in the well, the IC 50 measures the necessary dose to inhibit cell proliferation by 50%, and p represents the slope of the sigmoidal curve.
Pharmacokinetic Analysis
All animal experiments were done in accordance with Duke University's Institutional Animal Care and Use Committee. CP-Dox (15 mg Dox equivalents/kg body weight) was intravenously administered via tail vein into balb/c mice. 10 µL blood was collected at select time points from each mouse via tail vein nick (40 s, 5 min, 15 min, 2 h, 4 h, 8 h, 24 h, 48 h) and diluted into 100 µL of heparin in PBS (1000 U/mL). The samples were centrifuged (1000 g, 5 min, 4°C) to remove the red blood cells, and the Dox was released from the CP by incubating 10 µL of diluted plasma in 490 µL of acidified isopropanol (75 mM HCl, 90% isopropanol) for 16 h at 4°C. The solution was loaded into a 96-well microplate in triplicate (125 µL per well), and Dox fluorescence was determined on a Victor 3 microplate reader (485 nm excitation, 590 nm emission). Plasma concentration was fit to a two compartment model to determine the pharmacokinetic parameters using SAAM II software (University of Washington, Seattle, WA).
Biodistribution Analysis
Balb/c mice were inoculated with C26 tumors on their right hind leg (2.5x10 6 cells in 30 µL). Once the tumors reached ~100 mm 3 (approximately 9 days following inoculation), the mice were anaesthetized with 50 mg/kg body weight of nembutol (i.p. administration), and administered CP-Dox (15 mg Dox equivalents/kg body weight) via tail vein injection. The mice were placed in a custom hyperthermia holder with a rectal temperature probe to monitor the core body temperature and a plastic shield to prevent direct skin contact with the heated water. The mice were placed in a water bath set to 42.5°C, such that the tumor bearing leg was submerged just far enough to completely cover the tumor mass. A fan was used to regulate the body temperature.
To determine whole body biodistribution ( Figure S7A ), the mice were exposed to 1 h of continuous hyperthermia and were sacrificed 24 h following CP-Dox administration. To elucidate the effect of thermal cycling on tumor accumulation, mice were exposed to various hyperthermia schedules ( Figure 5 ) and were sacrificed 2 h following CP-Dox administration. Tissues were collected (heart, lungs, kidney, spleen, liver, muscle, and tumor), and 75-100 mg of tissue was weighed and suspended in 1 mL of acidified isopropanol (75 mM HCl, 90% isopropanol). The solution was homogenized using 2 mm Zirconia beads and a Beadbeater-16 (Biospec, Bartlesville, OK) for 120 s. The samples were incubated at 4°C for 16 h in the dark to release conjugated Dox. The samples were then centrifuged (4°C, 10 min, 14000 g), and the supernatant was fluorescently assayed as described in the pharmacokinetic analysis. Untreated tissues were similarly extracted and used to create a background curve (fluorescent counts/mg tissue) to compensate for tissue autofluorescence.
Window Chamber and Microscopy
Nude mice were anaesthetized with a cocktail of ketamine and xylazine (100 mg/kg ketamine, 10 mg/kg xylazine, i.p.) and implanted with a dorsal skin fold window chamber. A titanium chamber was surgically implanted over a 1-cm circular incision in the dorsal skin fold. FaDu human squamous carcinoma cells at a concentration of 2x10 6 cells in 30 µL of high glucose MEM were injected near the center of the window in the opposing layer of skin. The incision was then covered with a circular glass coverslip. All studies were performed 9-10 days following surgery, once the tumor reached a diameter of 2-3 mm.
To image the tumor vasculature, the mice were anaesthetized with 50 mg/kg body weight of nembutol and placed laterally recumbent upon a custom microscopy stage that enabled heating of the window chamber. The tail vein was cannulated and 100 µL of 5 mg/mL 2 MDa dextranfluorescein isothiocyanate (Invitrogen; Carlsbad, CA) was injected, followed by 200 µL of 425 µM CP nanoparticles (target plasma concentration of 50 µM) labeled with Rhodamine Red TM -X Succinimidyl Ester (Invitrogen). The temperature of the window was maintained at 37°C (physiological temperature) or 42°C (temperature achieved through mild hyperthermia). Images were taken with a Zeiss 780 upright confocal microscope. Data were obtained using two channels, in which dextran-fluorescein isothiocyanate was used to define the vasculature (Ex: 490 nm, Em: 525 nm), and the rhodamine channel was used to view the distribution of CP nanoparticles (Ex 540 nm: Em 625 nm). Upon injection of CPs at 37°C, fluorescent levels were adjusted to provide a yellow overlay. 
